CN111344008A - 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法 - Google Patents

用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法 Download PDF

Info

Publication number
CN111344008A
CN111344008A CN201880073897.7A CN201880073897A CN111344008A CN 111344008 A CN111344008 A CN 111344008A CN 201880073897 A CN201880073897 A CN 201880073897A CN 111344008 A CN111344008 A CN 111344008A
Authority
CN
China
Prior art keywords
rsv
protein
composition
rvsv
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880073897.7A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·涅维斯克
巴萨瓦拉杰·宾杰瓦达吉
李建荣
马克·皮普尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nationwide Childrens Hospital Inc
Ohio State Innovation Foundation
Original Assignee
Nationwide Childrens Hospital Inc
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Childrens Hospital Inc, Ohio State Innovation Foundation filed Critical Nationwide Childrens Hospital Inc
Publication of CN111344008A publication Critical patent/CN111344008A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880073897.7A 2017-09-15 2018-09-14 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法 Pending CN111344008A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762559167P 2017-09-15 2017-09-15
US62/559,167 2017-09-15
PCT/US2018/051054 WO2019055768A1 (en) 2017-09-15 2018-09-14 VACCINES AND METHODS OF MAKING AND USING VACCINES FOR THE PREVENTION OF SYNCYTIAL RESPIRATORY VIRUS (RSV) INFECTIONS

Publications (1)

Publication Number Publication Date
CN111344008A true CN111344008A (zh) 2020-06-26

Family

ID=65723867

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880073897.7A Pending CN111344008A (zh) 2017-09-15 2018-09-14 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法

Country Status (8)

Country Link
US (1) US20200276297A1 (enExample)
EP (1) EP3681523A4 (enExample)
JP (1) JP2020534284A (enExample)
KR (1) KR20200096904A (enExample)
CN (1) CN111344008A (enExample)
AU (1) AU2018331467A1 (enExample)
CA (1) CA3075990A1 (enExample)
WO (1) WO2019055768A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112226450A (zh) * 2020-08-25 2021-01-15 北京交通大学 一种共表达呼吸道合胞病毒融合前蛋白和黏附糖蛋白的复制缺陷型腺病毒载体疫苗
WO2024235338A1 (zh) * 2023-05-12 2024-11-21 中国科学院微生物研究所 一种呼吸道合胞病毒抗原制备方法和应用
WO2025077200A1 (zh) * 2023-10-12 2025-04-17 中国科学院微生物研究所 一种呼吸道合胞病毒二价抗原制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946446A1 (en) * 2019-04-02 2022-02-09 Sanofi Antigenic multimeric respiratory syncytial virus polypeptides
US20250127872A1 (en) * 2021-09-29 2025-04-24 Sk Bioscience Co., Ltd. Recombinant live attenuated rsv vaccine strain and production method therefor
KR102806300B1 (ko) * 2023-01-13 2025-05-14 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1224462A (zh) * 1996-07-15 1999-07-28 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
CN1347458A (zh) * 1999-04-13 2002-05-01 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒负链rna病毒疫苗
US20090162321A1 (en) * 2007-12-20 2009-06-25 Wyeth Methods for packaging propagation-defective vesicular stomatitis virus vectors using a stable cell line that expresses g protein
US20100247621A1 (en) * 2006-11-30 2010-09-30 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
CN102272295A (zh) * 2008-11-05 2011-12-07 默沙东公司 活减毒呼吸道合胞病毒
CN106659777A (zh) * 2014-06-13 2017-05-10 葛兰素史密丝克莱恩生物有限公司 免疫原性组合产品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264824A1 (en) * 2000-06-01 2001-12-11 St. Jude Children's Research Hospital Vaccine and gene therapy vector and methods of use thereof
AU2002327755A1 (en) * 2001-09-28 2003-04-14 Rush-Presbyterian-St. Luke's Medical Center Paramyxoviruses as gene transfer vectors to lung cells
CA2477235A1 (en) * 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
DE60330966D1 (de) * 2002-07-26 2010-03-04 Canada Natural Resources Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
KR100999316B1 (ko) * 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
ATE555208T1 (de) * 2003-06-13 2012-05-15 Apath Llc Replikon eines negativsträngigen rna-virus
US8287878B2 (en) * 2004-04-09 2012-10-16 Wyeth Llc Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
WO2009025770A2 (en) * 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
KR102416194B1 (ko) * 2014-03-01 2022-07-04 프로펙츄스 바이오사이언스, 인크. 재조합 이스파한 바이러스 벡터

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1224462A (zh) * 1996-07-15 1999-07-28 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
CN1347458A (zh) * 1999-04-13 2002-05-01 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒负链rna病毒疫苗
US20100247621A1 (en) * 2006-11-30 2010-09-30 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US20090162321A1 (en) * 2007-12-20 2009-06-25 Wyeth Methods for packaging propagation-defective vesicular stomatitis virus vectors using a stable cell line that expresses g protein
CN102272295A (zh) * 2008-11-05 2011-12-07 默沙东公司 活减毒呼吸道合胞病毒
CN106659777A (zh) * 2014-06-13 2017-05-10 葛兰素史密丝克莱恩生物有限公司 免疫原性组合产品

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDER BUKREYEV等: "The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing Leukocytes" *
XIANG LIU等: "Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F" *
YUANMEI MA等: "Heat Shock Protein 70 Enhances Mucosal Immunity against Human Norovirus When Coexpressed from a Vesicular Stomatitis Virus Vector" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112226450A (zh) * 2020-08-25 2021-01-15 北京交通大学 一种共表达呼吸道合胞病毒融合前蛋白和黏附糖蛋白的复制缺陷型腺病毒载体疫苗
WO2024235338A1 (zh) * 2023-05-12 2024-11-21 中国科学院微生物研究所 一种呼吸道合胞病毒抗原制备方法和应用
WO2025077200A1 (zh) * 2023-10-12 2025-04-17 中国科学院微生物研究所 一种呼吸道合胞病毒二价抗原制备方法和应用

Also Published As

Publication number Publication date
WO2019055768A1 (en) 2019-03-21
KR20200096904A (ko) 2020-08-14
CA3075990A1 (en) 2019-03-21
EP3681523A1 (en) 2020-07-22
AU2018331467A1 (en) 2020-04-30
JP2020534284A (ja) 2020-11-26
US20200276297A1 (en) 2020-09-03
EP3681523A4 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
CN111344008A (zh) 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法
JP2023513073A (ja) 呼吸器系ウイルス免疫化組成物
US7842295B2 (en) Canine influenza virus and related compositions and methods of use
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
JP2019510481A (ja) ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
HU229101B1 (en) Dna transfection system for the generation of infectious influenza virus
KR20100109933A (ko) 재조합 ｒｓｖ 항원
KR20150138184A (ko) 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
EP3049107A1 (en) Self-assembled nanoparticle vaccines
US11298417B2 (en) Measles virus vaccine expressing SARS-CoV-2 protein(s)
US20230174588A1 (en) A vaccine against sars-cov-2 and preparation thereof
US11576960B2 (en) Respiratory syncytial virus (RSV) vaccines
US20230310585A1 (en) Vaccine for viral pathogens
CN110996998A (zh) 表达rsv g的重组嵌合牛/人副流感病毒3及其用途
US20220370600A1 (en) Multigenic mva-sars-cov-2 vaccine
HK40029686A (en) Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
WO2017134202A1 (en) Fusion protein comprising the n protein of a virus of the pneumovirinae subfamily
ES2267510T3 (es) Acidos nucleicos y polipeptidos de lisavirus quimericos.
JP2023535902A (ja) コロナウイルスに対する免疫力を高める為の方法及び組成物
CN117599160A (zh) 狂犬病疫苗免疫原组合物
WO2023013785A1 (ja) Ｓｎａｒｅを活用した核酸構築物
US20100172925A1 (en) Hla-a2-restricted t-cell epitopes of the respiratory syncytial virus fusion protein as peptide-based vaccines
CA2535127C (en) H3 equine influenza a virus
KR20070092474A (ko) Ｈ3 말 인플루엔자 ａ 바이러스

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029686

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200626

WD01 Invention patent application deemed withdrawn after publication